Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
League One side will face either Sunderland or Fulham after knocking out Premier League leaders Chelsea.
Actress will play Belle in a live-action remake of Disney's animated film Beauty and the Beast.
ITV News hears the remarkable story of a Holocaust survivor who went on to marry the British soldier who liberated her from Bergen-Belsen.